BIOCHEMISTRY, BIOMEDICINE & PHARMACEUTICS

                  Multiple Choice Questions on  Immune Tolerance & Autoimmunity 1) Which of the following options is the mechanism for induction of immune tolerance? a) Central Anergy b) Peripheral Anergy c) Clonal Anergy d) All of the above 2) The central tolerance occurs in the thymus and bone marrow.  Which of the following statements is true regarding central tolerance ? a) The positive selection occurs in the cortex before maturing and entering the circulation. b) The negative selection occurs in the medulla. c) The negative selection removes cells that have high affinities for self-antigen d) All of the above 3) After exiting the thymus, mature T cells are subjected to the secondary selection where most self-reactive T cells are deleted or rendered anergic. The process is known as ............................................? a) Central Anergy b) Peripheral Anergy c) Clonal Anergy d) All of the a...

                  Aglucosidase (Myozyme)for the Treatment of Pompe Disease MYOZYME® (alpha-l-glucosidase alfa) Injectable for intravenous infusion: Pompe disease (glycogen storage disease type II, GSD II, glycogenosis type II, acid maltase deficiency) is an inherited disorder of glycogen metabolism caused by the absence or marked deficiency of the lysosomal enzyme GAA.  MYOZYME provides an exogenous source of GAA. Binding to mannose-6-phosphate receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalized and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity. It then exerts enzymatic activity in cleaving glycogen.  Initial U.S. Approval: 2006 INDICATIONS AND USAGE: MYOZYME® (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for use in patients with Pompe disease (GAA deficiency...